Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for…
<!-- Name:DistributionId Value:8829171 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
OnceatBedtime
Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and…
Discrete choice experiment demonstrated that number of doses was the most important attribute driving patient and clinician preference for oxybate therapy, with once-nightly dosing strongly…